bluebird bio Presents New Data from Clinical Studies of LentiGlobinTM Gene Therapy in Transfusion-Dependent β-Thalassemia at American Society of Hematology Annual Meeting

bluebird bio Announces Updated Clinical Results from Ongoing Phase 1 Multicenter Study of LentiGlobinâ„¢ Gene Therapy in Severe Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

GBT Announces New Phase 2a Data at ASH for Voxelotor in Adolescents with Sickle Cell Disease (SCD)

Magenta Therapeutics’ Lead Targeted Antibody Drug Conjugate Shows Promising Preclinical Results for Non-Genotoxic Conditioning for Bone Marrow Transplant

bluebird bio and TC BioPharm Announce Strategic Collaboration to Research and Develop Gamma Delta CAR T Cell Product Candidates for Cancer Immunotherapy